Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

Objective:  Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20–30 mg/kg/d reduces iron burden, depending on transfusional iron intake.

[1]  Roger W. Byard,et al.  CDC Growth Charts , 2010 .

[2]  E. Glimm,et al.  Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. , 2008, Blood.

[3]  S. Perrotta,et al.  A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. , 2006, Blood.

[4]  Y. Bertrand,et al.  Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. , 2006 .

[5]  J. Ford,et al.  Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. , 2006, Haematologica.

[6]  P. Marks,et al.  A Randomized, Controlled Phase II Trial in Sickle Cell Disease Patients with Chronic Iron Overload Demonstrates That the Once-Daily Oral Iron Chelator Deferasirox (Exjade ® , ICL670) Is Well Tolerated and Reduces Iron Burden. , 2005 .

[7]  L. Low.  Growth of children with β-thalassemia major , 2005 .

[8]  L. Low.  Growth of children with beta-thalassemia major. , 2005, Indian Journal of Pediatrics.

[9]  E. Vichinsky,et al.  A Phase II Study with ICL670 (Exjade®), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload. , 2004 .

[10]  E. Neufeld,et al.  Complications of beta-thalassemia major in North America. , 2004, Blood.

[11]  Matthew Darlison,et al.  Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.

[12]  A F Roche,et al.  CDC growth charts: United States. , 2000, Advance data.

[13]  E. Brunt,et al.  Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond , 2000, Hepatology.

[14]  N. Olivieri.  The β-Thalassemias , 1999 .

[15]  A. Piperno.  Classification and diagnosis of iron overload. , 1998, Haematologica.

[16]  M. Lakomek,et al.  Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion , 1997, European Journal of Pediatrics.

[17]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[18]  A. Piga,et al.  Results of long-term iron-chelating therapy. , 1996, Acta haematologica.

[19]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[20]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .

[21]  C. McLaren,et al.  Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.